- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Efficacy and Mechanisms of Midazolam in Inhibiting Cancer Progression
![Efficacy and Mechanisms of Midazolam in Inhibiting Cancer Progression Efficacy and Mechanisms of Midazolam in Inhibiting Cancer Progression](https://medicaldialogues.in/h-upload/2023/12/13/750x450_227804-cancer.webp)
Researchers have found in a new study that midazolam has the potential to impede cancer progression and decrease cancer cell survival. The new systematic review has been published in the Indian Journal of Anaesthesia.
The systematic review evaluated the potential role of midazolam in inhibiting cancer progression and reducing cancer cell survival. The review included 19 preclinical studies, which predominantly focused on in vitro experiments and some combination of in vitro and in vivo studies. The findings suggested that midazolam demonstrated potential anticancer properties, as it delayed cancer progression in 89% of the studies and reduced cancer cell survival in 63% of the studies. These effects were attributed to midazolam's ability to induce apoptosis and inhibit cancer cell proliferation, with demonstrated antimetastatic properties. The review also highlighted that midazolam might alter the efficacy of traditional anticancer agents, such as chemotherapy and immunotherapy. However, it noted that the mechanisms underlying these effects remain unclear due to the short-term nature of the in vitro and in vivo studies.
Limitations and Recommendations for Further Studies on Midazolam's Role in Cancer
The paper acknowledged conflicting literature on midazolam's role in cancer progression and the need for further investigation into its potential clinical implications. It highlighted the limitations of the included studies, such as the absence of clinical context, variability in experimental protocols and the need for additional clinical research to determine the appropriate dosage and assess the efficacy and safety of midazolam. The review recommended future studies to investigate the mechanisms underlying midazolam's effects on tumor growth and interactions with other cancer treatments. It also called for clinical trials to evaluate the impact of midazolam on cancer outcomes in patients undergoing cancer surgery or related procedures.
Conclusion of the Systematic Review on Midazolam's Potential in Cancer Therapy
In summary, the systematic review suggested that midazolam has the potential to impede cancer progression and decrease cancer cell survival based on preclinical evidence, although its clinical relevance and application require further investigation.
Reference -
Sethi, Ansh†; Rezk, Amal1,†; Couban, Rachel2; Chowdhury, Tumul1. Role of midazolam on cancer progression/survival - An updated systematic review. Indian Journal of Anaesthesia 67(11):p 951-961, November 2023. | DOI: 10.4103/ija.ija_731_23
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751